Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies

Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies

Abstract The addition of targeted therapies (TT) to endocrine therapy (ET) has improved the outcomes of patients with HR-positive, HER2-negative metastatic breast cancer (mBC). However, it is unknown whether patients with invasive lobular carcinoma (ILC) or mixed invasive ductal and lobular carcinom...

Full description

Bibliographic Details
Main Authors: Jason A. Mouabbi, Akshara Singareeka Raghavendra, Roland L. Bassett, Amy Hassan, Debu Tripathy, Rachel M. Layman
Format: Article
Language:English
Published: Nature Portfolio 2022-12-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-022-00499-7

Similar Items

Similar Items